• Pleuromutilin Binding at the Ribosomal PTC

  2026-10-02

  The 2006 study by Long and colleagues combined chemical footprinting, ribosomal structural information, and an Escherichia coli L3 mutant to clarify how pleuromutilin antibiotics occupy the peptidyl transferase center. Its central finding is that the conserved mutilin core anchors Tiamulin-class compounds, whereas side-chain contacts help determine rRNA remodeling and resistance behavior, providing a rational framework for derivative design.

• (S,S)-Nanaomycin A: DNMT3B Assay Guide

  2026-10-01

  Explore how (S,S)-Nanaomycin A can be used to interrogate DNMT3B-driven neuroendocrine plasticity in prostate cancer. This guide translates recent mechanistic findings into a state-aware experimental framework for distinguishing lineage reprogramming from nonspecific cytotoxicity.

• Prednisone: Mechanism, Evidence, and Bench Workflow

  2026-10-01

  Prednisone is a synthetic corticosteroid used in research on lymphocyte regulation, apoptosis, neurodegeneration, and corticosteroid pharmacology. Product-specific evidence describes G1-phase arrest, reduced IL-2 signaling, and dose- and time-dependent apoptosis in activated human peripheral blood lymphocytes.

• Doxorubicin Hydrochloride Research Workflow

  2026-09-30

  Build more informative cancer chemotherapy research workflows with Doxorubicin hydrochloride, from dose–response and apoptosis assays to mechanistic cardiotoxicity models. This guide connects practical assay design with a mouse study showing how oxidative stress, ferroptosis-related injury, and cardiac function can be evaluated together.

• Homer1a–Caspase-6 Signaling in Inflammatory Pain

  2026-09-30

  The reference study identifies a Homer1a/caspase-6/tumor necrosis factor-alpha axis that links synaptic signaling with microglial inflammation and thermal hypersensitivity. Pharmacologic inhibition and Homer1a overexpression both reduced pain-related outcomes in rats, supporting caspase-6 as a mechanistic node while leaving important questions about cell specificity, chronic pain, and translation unresolved.

• Spatially Concentrated ABEs Correct PLP1 Mutations

  2026-09-29

  The 2026 Nucleic Acids Research study introduces spatially concentrated adenine base editors that improve editing in oligodendrocytes by locally enriching TadA* at genomic targets rather than simply increasing catalytic activity. An AAV-compatible editor corrected PLP1 A243V, improved Plp localization, and rescued myelination-associated phenotypes, providing a preclinical framework for Pelizaeus–Merzbacher disease research.

• Plk1 Regulation of p31comet Checkpoint Disassembly

  2026-09-29

  The reference study identifies Polo-like kinase 1 (Plk1) as a direct regulator of p31comet-mediated mitotic checkpoint complex disassembly. By phosphorylating p31comet at S102, Plk1 suppresses TRIP13-dependent Mad2 release and may prevent premature checkpoint inactivation during active mitosis.

• 5-Azacytidine Workflow for DNA Demethylation

  2026-09-28

  Build reproducible 5-Azacytidine assays that connect promoter methylation with gene reactivation, epithelial-state changes, and cancer-cell responses. This practical workflow adapts recent HNF4A gastric-cancer findings while separating broad DNMT inhibition from locus-specific causal evidence.

• Triiodothyronine (T3): Signal Control for Translation

  2026-09-28

  A translational research perspective on using Triiodothyronine to interrogate receptor-driven biology, build reproducible cellular assays, and learn from precision strategies in gene editing—without conflating distinct mechanisms or disease domains.

• Plk1 Control of p31comet in Checkpoint Disassembly

  2026-09-27

  The study identifies Polo-like kinase 1 (Plk1) as a negative regulator of p31comet-mediated mitotic checkpoint complex disassembly, linking Plk1-dependent phosphorylation at S102 to reduced p31comet activity with TRIP13. The findings suggest a mechanism for maintaining checkpoint inhibition until conditions favor checkpoint inactivation, while highlighting the need to distinguish biochemical evidence from whole-cell outcomes.

• Aclacinomycin A and Persistent rDNA Damage

  2026-09-26

  Aclacinomycin A offers a useful way to investigate how topoisomerase-linked DNA stress intersects with nucleolar damage responses. This article connects its established cytotoxic mechanisms to evidence on persistent ribosomal DNA lesions and PML-nucleolar associations, while outlining experiments that can test the connection without assuming it.

• CA-074 Me for Lysosomal and Necroptosis Assays

  2026-09-25

  Use CA-074 Me to test whether intracellular cathepsin B contributes to lysosomal damage and cell death—not merely to measure a general loss of viability. This guide connects a mechanistic necroptosis study with practical inhibitor controls, live-cell readouts, and troubleshooting for cell-based and inflammation research.

• Self-Amplifying RNA Improves Influenza B Vaccine Responses

  2026-09-25

  This study compares nucleoside-modified mRNA, self-amplifying RNA, and circular RNA vaccine approaches for seasonal influenza. In mouse challenge experiments, a low-dose trivalent self-amplifying RNA vaccine generated durable antibody responses and protected against influenza B, addressing a weakness observed with the tested mRNA vaccine.

• 5-Azacytidine and the Biology of Tumor Dormancy

  2026-09-24

  5-Azacytidine is best known as a DNA demethylation agent, but its effects can extend beyond tumor-cell killing. Explore how a 5-AzaC combination study reframes epigenetic treatment as a way to establish metastatic-cell dormancy—and how to design experiments that distinguish dormancy from cytotoxicity.

• 5-Azacytidine Workflows for Viral Mimicry Research

  2026-09-24

  Learn how to use 5-Azacytidine to probe DNA methylation, gene reactivation, and viral-mimicry responses—with a practical workflow grounded in recent PTEN-deficient glioblastoma research. The article distinguishes reported findings from suggested pilot conditions and explains how to control for cytotoxicity and combination-treatment effects.

8029 records 1/536 page Next 12345 下5页 Last page